Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (12): 1177-1182.DOI: 10.3969/j.issn.1673-8640.2023.12.013
Previous Articles Next Articles
GU Yu1, LIANG Xiaoyan2, MA Shenghui1, TONG Na1, CHENG Mingyan1, YAN Zejun1()
Received:
2022-11-28
Revised:
2023-03-22
Online:
2023-12-30
Published:
2024-02-20
CLC Number:
GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism[J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.12.013
组别 | 例数 | DD/(mg/L) | GAS6/(ng/mL) | CD62P/% | Fib/(g/L) |
---|---|---|---|---|---|
研究组 | 93 | 1.43±0.42 | 14.53±4.31 | 13.61±4.08 | 2.83±0.84 |
对照组 | 93 | 0.98±0.29 | 10.46±3.14 | 9.35±2.81 | 2.01±0.60 |
t值 | 8.503 | 7.360 | 8.293 | 7.661 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | DD/(mg/L) | GAS6/(ng/mL) | CD62P/% | Fib/(g/L) |
---|---|---|---|---|---|
研究组 | 93 | 1.43±0.42 | 14.53±4.31 | 13.61±4.08 | 2.83±0.84 |
对照组 | 93 | 0.98±0.29 | 10.46±3.14 | 9.35±2.81 | 2.01±0.60 |
t值 | 8.503 | 7.360 | 8.293 | 7.661 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 性别 | 年龄/岁 | 体重指数/ (kg/m2) | CKD分期 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | 1期/[例(%)] | 2期/[例(%)] | 3期/[例(%)] | 4期/[例(%)] | 5期/[例(%)] | ||||||||||||
预后不良组 | 23 | 12 | 11 | 45.06±4.51 | 21.56±0.63 | 0(0.00) | 5(21.74) | 8(34.78) | 9(39.13) | 1(4.35) | ||||||||
预后良好组 | 70 | 37 | 33 | 43.98±5.62 | 21.64±0.55 | 5(7.14) | 15(21.43) | 24(34.29) | 23(32.86) | 3(4.29) | ||||||||
统计值 | 0.003 | 0.836 | 0.584 | 0.730 | ||||||||||||||
P值 | 0.955 | 0.405 | 0.561 | 0.466 | ||||||||||||||
组别 | 治疗方案 | 血栓栓塞类型 | 抗凝治疗 | 糖尿病史/[例(%)] | ||||||||||||||
肾脏替代疗法/[例(%)] | 护肾、降蛋白药物/[例(%)] | 肺栓塞/[例(%)] | 下肢深静脉血栓/[例(%)] | 有/[例(%)] | 无/[例(%)] | |||||||||||||
预后不良组 | 1(4.35) | 22(95.65) | 6(26.09) | 17(73.91) | 21(91.30) | 2(8.70) | 5(21.74) | |||||||||||
预后良好组 | 3(4.29) | 67(95.71) | 5(7.14) | 65(92.86) | 70(100.00) | 0(0.00) | 12(17.14) | |||||||||||
统计值 | 0.003 | 4.280 | 2.775 | 0.034 | ||||||||||||||
P值 | 0.958 | 0.038 | 0.096 | 0.326 | ||||||||||||||
组别 | 高血压病史/[例(%)] | 血栓史/[例(%)] | 遗传性易栓症/[例(%)] | DD/(mg/L) | GAS6/(ng/mL) | CD62P/% | Fib/(g/L) | |||||||||||
预后不良组 | 6(26.08) | 2(8.70) | 1(4.35) | 1.78±0.48 | 18.22±5.41 | 17.77±5.33 | 3.56±1.01 | |||||||||||
预后良好组 | 10(14.28) | 6(8.57) | 4(5.71) | 1.32±0.39 | 13.32±3.99 | 12.24±3.65 | 2.59±0.76 | |||||||||||
统计值 | 0.966 | 0.168 | 0.078 | 4.628 | 4.659 | 5.586 | 4.878 | |||||||||||
P值 | 0.326 | 0.682 | 0.778 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 性别 | 年龄/岁 | 体重指数/ (kg/m2) | CKD分期 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | 1期/[例(%)] | 2期/[例(%)] | 3期/[例(%)] | 4期/[例(%)] | 5期/[例(%)] | ||||||||||||
预后不良组 | 23 | 12 | 11 | 45.06±4.51 | 21.56±0.63 | 0(0.00) | 5(21.74) | 8(34.78) | 9(39.13) | 1(4.35) | ||||||||
预后良好组 | 70 | 37 | 33 | 43.98±5.62 | 21.64±0.55 | 5(7.14) | 15(21.43) | 24(34.29) | 23(32.86) | 3(4.29) | ||||||||
统计值 | 0.003 | 0.836 | 0.584 | 0.730 | ||||||||||||||
P值 | 0.955 | 0.405 | 0.561 | 0.466 | ||||||||||||||
组别 | 治疗方案 | 血栓栓塞类型 | 抗凝治疗 | 糖尿病史/[例(%)] | ||||||||||||||
肾脏替代疗法/[例(%)] | 护肾、降蛋白药物/[例(%)] | 肺栓塞/[例(%)] | 下肢深静脉血栓/[例(%)] | 有/[例(%)] | 无/[例(%)] | |||||||||||||
预后不良组 | 1(4.35) | 22(95.65) | 6(26.09) | 17(73.91) | 21(91.30) | 2(8.70) | 5(21.74) | |||||||||||
预后良好组 | 3(4.29) | 67(95.71) | 5(7.14) | 65(92.86) | 70(100.00) | 0(0.00) | 12(17.14) | |||||||||||
统计值 | 0.003 | 4.280 | 2.775 | 0.034 | ||||||||||||||
P值 | 0.958 | 0.038 | 0.096 | 0.326 | ||||||||||||||
组别 | 高血压病史/[例(%)] | 血栓史/[例(%)] | 遗传性易栓症/[例(%)] | DD/(mg/L) | GAS6/(ng/mL) | CD62P/% | Fib/(g/L) | |||||||||||
预后不良组 | 6(26.08) | 2(8.70) | 1(4.35) | 1.78±0.48 | 18.22±5.41 | 17.77±5.33 | 3.56±1.01 | |||||||||||
预后良好组 | 10(14.28) | 6(8.57) | 4(5.71) | 1.32±0.39 | 13.32±3.99 | 12.24±3.65 | 2.59±0.76 | |||||||||||
统计值 | 0.966 | 0.168 | 0.078 | 4.628 | 4.659 | 5.586 | 4.878 | |||||||||||
P值 | 0.326 | 0.682 | 0.778 | <0.001 | <0.001 | <0.001 | <0.001 |
自变量 | 赋值 | β值 | 标准误 | Wald值 | OR值①(95%CI②) | P值 |
---|---|---|---|---|---|---|
GAS6 | 实测值 | 1.893 | 0.563 | 11.303 | 6.638 (3.118~14.132) | <0.001 |
CD62P | 实测值 | 1.749 | 0.398 | 19.303 | 5.747 (1.765~18.711) | <0.001 |
DD | 实测值 | 2.002 | 0.414 | 23.386 | 7.404 (4.426~12.387) | <0.001 |
Fib | 实测值 | 2.283 | 0.602 | 14.379 | 9.804 (2.789~34.462) | <0.001 |
自变量 | 赋值 | β值 | 标准误 | Wald值 | OR值①(95%CI②) | P值 |
---|---|---|---|---|---|---|
GAS6 | 实测值 | 1.893 | 0.563 | 11.303 | 6.638 (3.118~14.132) | <0.001 |
CD62P | 实测值 | 1.749 | 0.398 | 19.303 | 5.747 (1.765~18.711) | <0.001 |
DD | 实测值 | 2.002 | 0.414 | 23.386 | 7.404 (4.426~12.387) | <0.001 |
Fib | 实测值 | 2.283 | 0.602 | 14.379 | 9.804 (2.789~34.462) | <0.001 |
项目 | AUC | 95%CI | 临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|---|
GAS6 | 0.763 | 0.664~0.845 | 13.51 ng/mL | 95.65 | 52.86 | 0.485 |
CD62P | 0.824 | 0.731~0.895 | 17.19 % | 65.22 | 87.14 | 0.524 |
Fib | 0.794 | 0.698~0.871 | 3.12 g/L | 73.91 | 80.00 | 0.539 |
DD | 0.784 | 0.687~0.863 | 1.63 mg/L | 65.22 | 85.71 | 0.510 |
项目 | AUC | 95%CI | 临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|---|
GAS6 | 0.763 | 0.664~0.845 | 13.51 ng/mL | 95.65 | 52.86 | 0.485 |
CD62P | 0.824 | 0.731~0.895 | 17.19 % | 65.22 | 87.14 | 0.524 |
Fib | 0.794 | 0.698~0.871 | 3.12 g/L | 73.91 | 80.00 | 0.539 |
DD | 0.784 | 0.687~0.863 | 1.63 mg/L | 65.22 | 85.71 | 0.510 |
项目 | AUC差异 | 标准误 | 95%CI下限 | 95%CI上限 | Z值 | P值 |
---|---|---|---|---|---|---|
GAS6+CD62P+DD | 0.009 | 0.041 | -0.072 | 0.091 | 0.221 | >0.05 |
GAS6+CD62P+Fib | 0.008 | 0.047 | -0.096 | 0.098 | 0.158 | >0.05 |
CD62P+Fib+DD | 0.001 | 0.050 | -0.096 | 0.098 | 0.103 | >0.05 |
项目 | AUC差异 | 标准误 | 95%CI下限 | 95%CI上限 | Z值 | P值 |
---|---|---|---|---|---|---|
GAS6+CD62P+DD | 0.009 | 0.041 | -0.072 | 0.091 | 0.221 | >0.05 |
GAS6+CD62P+Fib | 0.008 | 0.047 | -0.096 | 0.098 | 0.158 | >0.05 |
CD62P+Fib+DD | 0.001 | 0.050 | -0.096 | 0.098 | 0.103 | >0.05 |
[1] |
RUIZ-ORTEGA M, RAYEGO-MATEOS S, LAMAS S, et al. Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol, 2020, 16(5):269-288.
DOI |
[2] |
CHEUNG C Y S, PARIKH J, FARRELL A, et al. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism:a systematic review of thrombosis and bleeding outcomes[J]. Ann Pharmacother, 2021, 55(6):711-722.
DOI URL |
[3] |
CHENG J, FU Z, ZHU J, et al. The predictive value of plasminogen activator inhibitor-1,fibrinogen,and D-dimer for deep venous thrombosis following surgery for traumatic lower limb fracture[J]. Ann Palliat Med, 2020, 9(5):3385-3392.
DOI URL |
[4] | 吴忠勇, 王金忠, 周森, 等. 基于Notch信号通路的黄芩素抑制急性肺栓塞模型大鼠血小板聚集及肺组织保护作用机制研究[J]. 中国药房, 2020, 31(9):1091-1097. |
[5] | 李迪, 吕永楠, 刘欢, 等. 生长停滞特异性蛋白6与急性心肌梗死的相关性研究[J]. 中华检验医学杂志, 2020, 43(3):302-306. |
[6] | 葛均波, 徐永健. 内科学[M]. 8版. 北京: 人民卫生出版社, 2013. |
[7] | 王乔宇, 武明芬, 柳鑫, 等. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志, 2021, 37(21):2999-3016. |
[8] | 白黎峰, 张倩, 郑院青, 等. 血清Hcy、D-D、FIB联合预测急性肺血栓栓塞患者远期预后不良的价值探讨[J]. 临床肺科杂志, 2021, 26(5):718-722. |
[9] | 高翔, 李含静, 张明佳. 介入治疗急性下肢深静脉血栓形成合并骼静脉压迫综合征的疗效及安全性分析[J]. 系统医学, 2022, 7(11):52-55. |
[10] | 谢晖, 沈瀚. 慢性肾脏病患者凝血功能变化及高凝状态影响因素分析[J]. 检验医学, 2021, 36(5):500-503. |
[11] |
KUMA A, MAFUNE K, UCHINO B, et al. Potential link between high FIB-4 score and chronic kidney disease in metabolically healthy men[J]. Sci Rep, 2022, 12(1):16638.
DOI PMID |
[12] | 郝君霞, 胡金花, 夏群, 等. 2D-B/W、CDFI联合血浆Fib、D-D检测对DVT的诊断价值[J]. 中国医药导报, 2022, 19(7):104-107. |
[13] | 孙成爱, 周新华, 任玉菊, 等. 联合D-二聚体及GRACE评分预测急性肺栓塞预后的价值[J]. 湖南师范大学学报(医学版), 2021, 18(5):244-246. |
[14] |
BRANCHFORD B R, STALKER T J, LAW L, et al. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis[J]. J Thromb Haemost, 2018, 16(2):352-363.
DOI PMID |
[15] | 谢崧璞, 刘承云. GAS6/TAM信号通路在止血和血栓形成中的作用研究进展[J]. 医学综述, 2021, 27(15):2924-2928. |
[16] | 李斌, 邓修高, 李金, 等. 维持性血液透析患者血浆生长停滞特异性蛋白6水平与动静脉内瘘血栓形成的关系[J]. 临床肾脏病杂志, 2022, 22(9):737-741. |
[17] |
BATTINELLI E M, THON J N, OKAZAKI R, et al. Megakaryocytes package contents into separate α-granules that are differentially distributed in platelets[J]. Blood Adv, 2019, 3(20):3092-3098.
DOI PMID |
[18] | 张丽媛, 陈璐, 李春晓, 等. 川芎嗪通过抑制ERK5/P70S6K/Rac1信号通路发挥抗血小板活化及血栓形成作用[J]. 中华中医药学刊, 2021, 39(2):135-139. |
[19] |
LUCAS T C, CARVALHO M D G, DUARTE R C F, et al. Effect of the expression of CD62P and thrombin generation on patients using central venous catheters for hemodialysis[J]. Artif Organs, 2020, 44(3):296-304.
DOI PMID |
[20] | 黑国真, 蔡蕊, 李昱, 等. 血小板聚集率对产后下肢深静脉血栓形成的预测价值及其可能机制[J]. 中国妇幼保健, 2020, 35(17):3147-3150. |
[21] | 杨月, 刘露, 于世寰, 等. 丹参川芎嗪注射液对肺栓塞大鼠P-选择素及组织因子的影响[J]. 国际呼吸杂志, 2020, 40(6):417-422. |
[1] | XIA Yanyan, XIA Yongquan, SONG Guanghao, XIA Mao. Role of coagulation-related monitoring indicators in the course of rivaroxaban anticoagulation for acute venous thromboembolism in elderly patients [J]. Laboratory Medicine, 2023, 38(5): 475-478. |
[2] | DENG Xu, ZHUANG Wenlong, XUE Hui, ZHU Shuqin, LI Ying. Relationship between neutrophil/lymphocyte ratio,fibrinogen and carotid intima-media thickness in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(4): 368-372. |
[3] | HU Bing, LI Gai, ZHANG Huimin. Roles of serum interleukin-6 and D-dimer levels in predicting the risk of cerebral hemorrhage in patients with hypertension [J]. Laboratory Medicine, 2022, 37(1): 63-67. |
[4] | XIE Hui, SHEN Han. Changes of coagulation function and influence factors of hypercoagulability in patients with chronic kidney disease [J]. Laboratory Medicine, 2021, 36(5): 500-503. |
[5] | DING Ning, ZHANG Weifeng, CHEN Xiaoyong, ZHAO Kewen. Correlations of mean platelet volume,D-dimer and fibrinogen degradation product levels with cerebral infarction and its pathological degree [J]. Laboratory Medicine, 2021, 36(4): 384-387. |
[6] | WU Huiwen, LI Luoping, XING Xiaozhong, WAN Dayong. Clinical value of combined detection of RBP,CRP and UMA in patients with chronic renal disease and ischemic cerebrovascular disease [J]. Laboratory Medicine, 2021, 36(3): 304-308. |
[7] | ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193. |
[8] | CHEN Yiming, HUANG Jianxia, SHI Xiaochun, HE Pei, SHEN Yonghai. Diagnostic value of maternal plasma D-dimer and hypertensive disorders of pregnancy in late pregnancy [J]. Laboratory Medicine, 2020, 35(8): 753-756. |
[9] | LIU Qin, CHEN Chong, YUE Chao. Role of an elevated D-dimer cut-off value for the prognosis of lung cancer [J]. Laboratory Medicine, 2020, 35(8): 763-766. |
[10] | WANG Bin, YUAN Xu, HAN Feng, TANG Ning. Relevant factors on short-term critical events in patients with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(6): 540-545. |
[11] | CHEN Xing, OU Jingyi, HUANG Ying, TAN Mingkai, CHEN Jiabin, LIN Luping, LIANG Zhiwei, SHI Yaling. Diagnostic roles of several parameters in corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(4): 295-299. |
[12] | zhou YE Ping, DONG Xuemei, ZHANG Chong, DU Xiaozhong. Analysis on the results of coagulation four parameters and D-dimer in healthy pregnant women in Lan [J]. Laboratory Medicine, 2020, 35(4): 334-337. |
[13] | MENG Hongbing, CAO Xingjian, FAN Yuping, GU Shuijing, LI Na. Diagnostic value of D-dimer level in different types of pancreatitis [J]. Laboratory Medicine, 2020, 35(3): 260-263. |
[14] | ZHENG Wei, HAO Aijun, ZHU Guoyong, ZHANG Yinhui, WANG Dongyun, PANg Jie. Clinical roles of SAA,CRP,LYMPH#,NT-proBNP and DD in COVID-19 [J]. Laboratory Medicine, 2020, 35(12): 1238-1242. |
[15] | SHANG Xinrong, CHI Lin, SUI Wenjun. Predictive role of plasma D-dimer and fibrinogen degradation product in pre-eclampsia [J]. Laboratory Medicine, 2020, 35(12): 1252-1254. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||